Skip to main content
. 2018 Nov 5;115(47):12023–12027. doi: 10.1073/pnas.1812833115

Fig. 6.

Fig. 6.

(A) The binding of glycoengineered cetuximab (9) and commercial cetuximab with EGFR on A431 cells. (B) ADCC assays conducted using a 1:1 ratio of effector and target cells. ADCC activity was assessed by measuring the percent CD107a+ NK cell populations by FACS. Red box, Glycoengineered cetuximab (9); blue circle, commercial cetuximab; black triangle, antibody isotype control.